⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

March 4, 2024Open Access

Supplementary Figure S1 from Dual CAR-T Cells Targeting CD19 and CD37 Are Effective in Target Antigen Loss B-cell Tumor Models

Kanae Imai Yuki Takeuchi Seitaro Terakura Shingo Okuno Yoshitaka Adachi Masahide Osaki Koji Umemura Ryo Hanajiri Kazuyuki Shimada Makoto Murata Hitoshi Kiyoi

View Full Paper

Ask AI

Bookmark

Share

Abstract

Supplemental Figure S1. CD19 and CD37 expression of EBV-LCL. EBV-LCL was stained with CD19-PE and CD37-FITC mAb, respectively. Grey tinted area indicated isotype control staining.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Imai et al. (2024) studied this question.

synapsesocial.com/papers/68e75dd0b6db6435876d4c0d https://doi.org/10.1158/1535-7163.25337992

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure S1 from Dual CAR-T Cells Targeting CD19 and CD37 Are Effective in Target Antigen Loss B-cell Tumor Models2024
2Supplementary Figure S3 from Dual CAR-T Cells Targeting CD19 and CD37 Are Effective in Target Antigen Loss B-cell Tumor Models2024
3Supplementary Figure S3 from Dual CAR-T Cells Targeting CD19 and CD37 Are Effective in Target Antigen Loss B-cell Tumor Models2024
4Supplementary FIgure S2 from Dual CAR-T Cells Targeting CD19 and CD37 Are Effective in Target Antigen Loss B-cell Tumor Models2024
5Supplementary FIgure S2 from Dual CAR-T Cells Targeting CD19 and CD37 Are Effective in Target Antigen Loss B-cell Tumor Models2024

More related papers

Data from Dual CAR-T Cells Targeting CD19 and CD37 Are Effective in Target Antigen Loss B-cell Tumor Models2024
Preclinical development of CD37CAR T-cell therapy for treatment of B-cell lymphoma2019
Supplementary Figure 2 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited2025